Patient stomps out kidney cancer thanks to IL-2 treatment, healthy living
Janet Fatika, 70, loves to walk. She treks up to a mile and half every day with her sister.
Feb 5, 2016
0
14
Janet Fatika, 70, loves to walk. She treks up to a mile and half every day with her sister.
Feb 5, 2016
0
14
All cells need nutrients, but cancer cells are notoriously power hungry. As a result, cancer cells must alter their metabolism to provide the additional fuel needed for them to survive, grow and spread.
Feb 3, 2016
0
52
Federal health regulators have expanded approval of a cancer drug from Bristol-Myers Squibb to treat an advanced form of kidney cancer.
Nov 23, 2015
0
0
Diets high in meat may lead to an increased risk of developing renal cell carcinoma (RCC) through intake of carcinogenic compounds created by certain cooking techniques, such as barbecuing and pan-frying. As part of a new ...
Nov 9, 2015
0
344
Scientists with The Cancer Genome Atlas (TCGA), a National Institutes of Health-funded project, have molecularly characterized two types of the second most common kidney cancer and classified several subtypes of the disease.
Nov 5, 2015
0
9
(HealthDay)—Older kidney cancer patients treated with sorafenib or sunitinib may face an increased risk of cardiovascular adverse events, according to a study published online Oct. 6 in Cancer.
Oct 13, 2015
0
7
The first mouse model of an aggressive form of kidney cancer has identified an Achilles' heel in the disease that could lead to new treatment approaches in humans, according to a study by researchers at the School of Medicine.
May 12, 2015
2
85
A higher intake by postmenopausal women of the natural antioxidant lycopene, found in foods like tomatoes, watermelon and papaya, may lower the risk of renal cell carcinoma, a type of kidney cancer.
Mar 2, 2015
0
12
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was ...
Feb 24, 2015
0
5
Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent (sunitinib) or Nexavar (sorafenib) among patients with locally advanced renal cell carcinoma ...
Feb 24, 2015
0
9